A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
Market
0.0%
Details
- Resolved Date
- 5/8/25
- Study Completion
- 3/1/26
- Company
- Zai Lab (Hong Kong), Ltd.
- Ticker
- ZLAB
- Type
- Trial Status
- Recruiting
- Trial Size
- 250
- Volume
- $0
- NCT
- NCT06380907
- Drug Description
- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
Resolution Evidence
- Outcome
- NO
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Sponsor publicly said it discontinued this exact Phase 2 ZL-1102 psoriasis trial after reviewing interim data from the first 40 patients, following the independent Data and Safety Monitoring Board’s recommendation. That is a clearly negative trial-specific readout, not a positive one.
Sources
Sponsorir.zailaboratory.com5/8/25
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
Zai Lab said it decided to discontinue the global Phase 2 clinical trial of ZL-1102 after reviewing interim data from the first 40 enrolled participants and a recommendation from the independent Data and Safety Monitoring Board.
View source
Sponsorir.zailaboratory.com5/8/25
Form 10-Q for ZAI LAB LTD filed 05/08/2025
The company stated it decided to discontinue the global Phase II clinical trial of ZL-1102 following interim analysis from the first 40 participants and the board’s recommendation.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
